The oncology combination therapy market is expanding due to growing cancer incidence, improved survival rates with synergistic drug combinations, and ongoing innovations in immunotherapy and targeted treatments. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncology Combination Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncology Combination Therapy Market, by Therapy Type
8.1.1. Chemotherapy + Targeted Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunotherapy + Chemotherapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Immunotherapy + Targeted Therapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Dual Immunotherapy (PD-1 + CTLA-4, etc.)
8.1.4.1. Market Revenue and Forecast
8.1.5. Radiation + Systemic Therapies
8.1.5.1. Market Revenue and Forecast
8.1.6. Hormonal + Targeted Therapy
8.1.6.1. Market Revenue and Forecast
9.1. Oncology Combination Therapy Market, by Drug Class Combination
9.1.1. Small Molecules + Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast
9.1.2. Checkpoint Inhibitors + Kinase Inhibitors
9.1.2.1. Market Revenue and Forecast
9.1.3. Cytotoxics + Immune Modulators
9.1.3.1. Market Revenue and Forecast
9.1.4. Antibody-Drug Conjugates + Chemotherapy
9.1.4.1. Market Revenue and Forecast
9.1.5. Cell Therapy + Checkpoint Inhibitors
9.1.5.1. Market Revenue and Forecast
10.1. Oncology Combination Therapy Market, by Cancer Type
10.1.1. Non-Small Cell Lung Cancer (NSCLC)
10.1.1.1. Market Revenue and Forecast
10.1.2. Triple-Negative Breast Cancer (TNBC)
10.1.2.1. Market Revenue and Forecast
10.1.3. Colorectal Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Melanoma
10.1.4.1. Market Revenue and Forecast
10.1.5. Blood Cancers (Lymphoma, Leukemia)
10.1.5.1. Market Revenue and Forecast
10.1.5. Prostate and Bladder Cancers
10.1.5.1. Market Revenue and Forecast
11.1. Oncology Combination Therapy Market, by Route of Administration
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast
11.1.2. Oral
11.1.2.1. Market Revenue and Forecast
11.1.3. Subcutaneous (SC)
11.1.3.1. Market Revenue and Forecast
11.1.4. Intratumoral
11.1.4.1. Market Revenue and Forecast
12.1. Oncology Combination Therapy Market, by Treatment Intent
12.1.1. First-Line Therapy
12.1.1.1. Market Revenue and Forecast
12.1.2. Second-Line and Salvage Therapy
12.1.2.1. Market Revenue and Forecast
12.1.3. Neoadjuvant and Adjuvant Therapy
12.1.3.1. Market Revenue and Forecast
12.1.4. Maintenance Therapy
12.1.4.1. Market Revenue and Forecast
13.1. Oncology Combination Therapy Market, by End-User
13.1.1. Specialty Cancer Hospitals
13.1.1.1. Market Revenue and Forecast
13.1.2. Academic & Research Institutions
13.1.2.1. Market Revenue and Forecast
13.1.3. Outpatient Oncology Clinics
13.1.3.1. Market Revenue and Forecast
13.1.4. Homecare (limited to oral combinations)
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapy Type
14.1.2. Market Revenue and Forecast, by Drug Class Combination
14.1.3. Market Revenue and Forecast, by Cancer Type
14.1.4. Market Revenue and Forecast, by Route of Administration
14.1.5. Market Revenue and Forecast, by Treatment Intent
14.1.6. Market Revenue and Forecast, by End-User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapy Type
14.1.7.2. Market Revenue and Forecast, by Drug Class Combination
14.1.7.3. Market Revenue and Forecast, by Cancer Type
14.1.7.4. Market Revenue and Forecast, by Route of Administration
14.1.8. Market Revenue and Forecast, by Treatment Intent
14.1.8.1. Market Revenue and Forecast, by End-User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapy Type
14.1.9.2. Market Revenue and Forecast, by Drug Class Combination
14.1.9.3. Market Revenue and Forecast, by Cancer Type
14.1.9.4. Market Revenue and Forecast, by Route of Administration
14.1.10. Market Revenue and Forecast, by Treatment Intent
14.1.11. Market Revenue and Forecast, by End-User
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapy Type
14.2.2. Market Revenue and Forecast, by Drug Class Combination
14.2.3. Market Revenue and Forecast, by Cancer Type
14.2.4. Market Revenue and Forecast, by Route of Administration
14.2.5. Market Revenue and Forecast, by Treatment Intent
14.2.6. Market Revenue and Forecast, by End-User
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapy Type
14.2.8.2. Market Revenue and Forecast, by Drug Class Combination
14.2.8.3. Market Revenue and Forecast, by Cancer Type
14.2.9. Market Revenue and Forecast, by Route of Administration
14.2.10. Market Revenue and Forecast, by Treatment Intent
14.2.10.1. Market Revenue and Forecast, by End-User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapy Type
14.2.11.2. Market Revenue and Forecast, by Drug Class Combination
14.2.11.3. Market Revenue and Forecast, by Cancer Type
14.2.12. Market Revenue and Forecast, by Route of Administration
14.2.13. Market Revenue and Forecast, by Treatment Intent
14.2.14. Market Revenue and Forecast, by End-User
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapy Type
14.2.15.2. Market Revenue and Forecast, by Drug Class Combination
14.2.15.3. Market Revenue and Forecast, by Cancer Type
14.2.15.4. Market Revenue and Forecast, by Route of Administration
14.2.16. Market Revenue and Forecast, by Treatment Intent
14.2.16.1. Market Revenue and Forecast, by End-User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapy Type
14.2.17.2. Market Revenue and Forecast, by Drug Class Combination
14.2.17.3. Market Revenue and Forecast, by Cancer Type
14.2.17.4. Market Revenue and Forecast, by Route of Administration
14.2.18. Market Revenue and Forecast, by Treatment Intent
14.2.18.1. Market Revenue and Forecast, by End-User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapy Type
14.3.2. Market Revenue and Forecast, by Drug Class Combination
14.3.3. Market Revenue and Forecast, by Cancer Type
14.3.4. Market Revenue and Forecast, by Route of Administration
14.3.5. Market Revenue and Forecast, by Treatment Intent
14.3.6. Market Revenue and Forecast, by End-User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapy Type
14.3.7.2. Market Revenue and Forecast, by Drug Class Combination
14.3.7.3. Market Revenue and Forecast, by Cancer Type
14.3.7.4. Market Revenue and Forecast, by Route of Administration
14.3.8. Market Revenue and Forecast, by Treatment Intent
14.3.9. Market Revenue and Forecast, by End-User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapy Type
14.3.10.2. Market Revenue and Forecast, by Drug Class Combination
14.3.10.3. Market Revenue and Forecast, by Cancer Type
14.3.10.4. Market Revenue and Forecast, by Route of Administration
14.3.11. Market Revenue and Forecast, by Treatment Intent
14.3.11.1. Market Revenue and Forecast, by End-User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapy Type
14.3.12.2. Market Revenue and Forecast, by Drug Class Combination
14.3.12.3. Market Revenue and Forecast, by Cancer Type
14.3.12.4. Market Revenue and Forecast, by Route of Administration
14.3.12.5. Market Revenue and Forecast, by Treatment Intent
14.3.12.6. Market Revenue and Forecast, by End-User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapy Type
14.3.13.2. Market Revenue and Forecast, by Drug Class Combination
14.3.13.3. Market Revenue and Forecast, by Cancer Type
14.3.13.4. Market Revenue and Forecast, by Route of Administration
14.3.13.5. Market Revenue and Forecast, by Treatment Intent
14.3.13.6. Market Revenue and Forecast, by End-User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapy Type
14.4.2. Market Revenue and Forecast, by Drug Class Combination
14.4.3. Market Revenue and Forecast, by Cancer Type
14.4.4. Market Revenue and Forecast, by Route of Administration
14.4.5. Market Revenue and Forecast, by Treatment Intent
14.4.6. Market Revenue and Forecast, by End-User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapy Type
14.4.7.2. Market Revenue and Forecast, by Drug Class Combination
14.4.7.3. Market Revenue and Forecast, by Cancer Type
14.4.7.4. Market Revenue and Forecast, by Route of Administration
14.4.8. Market Revenue and Forecast, by Treatment Intent
14.4.9. Market Revenue and Forecast, by End-User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapy Type
14.4.10.2. Market Revenue and Forecast, by Drug Class Combination
14.4.10.3. Market Revenue and Forecast, by Cancer Type
14.4.10.4. Market Revenue and Forecast, by Route of Administration
14.4.11. Market Revenue and Forecast, by Treatment Intent
14.4.12. Market Revenue and Forecast, by End-User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapy Type
14.4.13.2. Market Revenue and Forecast, by Drug Class Combination
14.4.13.3. Market Revenue and Forecast, by Cancer Type
14.4.13.4. Market Revenue and Forecast, by Route of Administration
14.4.13.5. Market Revenue and Forecast, by Treatment Intent
14.4.13.6. Market Revenue and Forecast, by End-User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapy Type
14.4.14.2. Market Revenue and Forecast, by Drug Class Combination
14.4.14.3. Market Revenue and Forecast, by Cancer Type
14.4.14.4. Market Revenue and Forecast, by Route of Administration
14.4.14.5. Market Revenue and Forecast, by Treatment Intent
14.4.14.6. Market Revenue and Forecast, by End-User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapy Type
14.5.2. Market Revenue and Forecast, by Drug Class Combination
14.5.3. Market Revenue and Forecast, by Cancer Type
14.5.4. Market Revenue and Forecast, by Route of Administration
14.5.5. Market Revenue and Forecast, by Treatment Intent
14.5.6. Market Revenue and Forecast, by End-User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapy Type
14.5.7.2. Market Revenue and Forecast, by Drug Class Combination
14.5.7.3. Market Revenue and Forecast, by Cancer Type
14.5.7.4. Market Revenue and Forecast, by Route of Administration
14.5.8. Market Revenue and Forecast, by Treatment Intent
14.5.8.1. Market Revenue and Forecast, by End-User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapy Type
14.5.9.2. Market Revenue and Forecast, by Drug Class Combination
14.5.9.3. Market Revenue and Forecast, by Cancer Type
14.5.9.4. Market Revenue and Forecast, by Route of Administration
14.5.9.5. Market Revenue and Forecast, by Treatment Intent
14.5.9.6. Market Revenue and Forecast, by End-User
15.1. Roche Holding AG
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Merck & Co., Inc. (Keytruda)
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Bristol Myers Squibb
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Pfizer Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. AstraZeneca plc
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Abbott
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Novartis AG
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Eli Lilly and Company
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Amgen Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Gilead Sciences, Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description